CompletedPhase 1

A Relative Bioavailability Study of LY3209590 in Healthy Participants

Singapore168 participantsStarted 2022-11-11

Plain-language summary

The study will be conducted in two parts (part A and part B). The main purpose of this study is to compare the amount of LY3209590 that gets into the blood stream and how long it takes the body to get rid of it, when self-administered at different body sites, abdominal wall, upper arm and thigh (part A), when administered by two different routes of injection, subcutaneously or intravenously (part B) in healthy participants. The study may last up to 65 (part A) and 184 (part B) days, respectively.

Who can participate

Age range21 Years – 65 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Male or female participants who are overtly healthy as determined by medical evaluation * Participants with body mass index (BMI) within the range 18.5 to 35.0 kilograms per meter squared (kg/m²) * Male or female participants must agree to use contraception Exclusion Criteria: * Have a history of multiple or severe allergic reactions or a history of severe anaphylactic reaction * Have known allergies to LY3209590, related compounds, or any components of the formulation * Have an abnormality in the 12-lead electrocardiogram * Intend to use prescription medication, including herbal medications and traditional medications * Show evidence of human immunodeficiency virus infection or positive human immunodeficiency virus antibodies, hepatitis C or positive hepatitis C antibody, or hepatitis B or positive hepatitis B surface antigen * Are lactating or pregnant

What they're measuring

Part A: Pharmacokinetics (PK): Area Under the Plasma Concentration Versus Time Curve From Zero to Infinity (AUC[0-∞]) of LY3209590

Timeframe: Predose on Day 1 through Day 65

Trial details

NCT IDNCT05615532

SponsorEli Lilly and Company

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2023-06-28